China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced receiving another marketing approval from the National Medical Products Administration (NMPA) for its Category 1 product, ciprofol injection, for use in gynecology outpatient sedation/anesthesia. This approval expands the indications for ciprofol, further solidifying its position in the anesthetic market.
Drug Profile and Mechanism
Ciprofol is a novel intravenous anesthetic that acts as a GABAA receptor agonist. By interacting with the chloride channel mediated by the GABAA receptor, it increases current conduction and causes hyperpolarization of neurons. This hyperpolarization leads to consistent transmission of neural signals and reduces the success rate of action potential generation, thereby inhibiting the central nervous system and producing anesthetic effects. Ciprofol has demonstrated a good overall safety and tolerance profile.
Comparative Advantages
Compared to propofol, ciprofol exhibits pharmacodynamic activity that is about five times greater. It also offers superior effects on respiration, non-inferior effects on heart rate and blood pressure, and less lipid infusion. These characteristics make ciprofol a valuable addition to the anesthetic arsenal, particularly for outpatient procedures.
Previous Approvals and Future Outlook
Previously, ciprofol was approved for use in sedation and anesthesia during operations without endotracheal intubation, general anesthesia induction, and maintenance and sedation during intensive care. The latest approval for gynecology outpatient sedation/anesthesia further broadens its clinical applications. This expansion underscores Haisco Pharmaceutical’s commitment to providing innovative anesthetic solutions and enhancing patient care in various medical settings.-Fineline Info & Tech
